NBTX — Nanobiotix S.A.
$29.36+0.58%
Last close: · regular session
Last 60 sessions
NBTX closed at $29.36 (+0.58%) on Oct 23, 2026. Float: 41.4M shares. Latest SEC filing: 6-K on Jun 5, 2026.
Opening the full analysis uses 1 of your 3 free tickers today.
Chart, dilution, float and news for NBTX in the TickerWise workspace.
Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. Nanobiotix S.A. has a partnership with LianBio to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. The company was incorporated in 2003 and is headquartered in Paris, France.
Company profile
- Sector: Healthcare
- Industry: Biotechnology
- Country: FR
- Exchange: NASDAQ
- Employees: 108
- Website: https://www.nanobiotix.com
Latest SEC filings for NBTX
Latest NBTX news
- NANOBIOTIX Announces Final Data from Phase 1 Study Evaluating JNJ-1900 (NBTXR3) With Immune Checkpoint Inhibitors as a 2L+ Therapy in Anti-PD-1-Resistant Primary Cutaneous Melanoma Read article
- NANOBIOTIX annonce les résultats complets de l’étude de Phase 1 évaluant JNJ-1900 (NBTXR3) en combinaison avec des inhibiteurs de points de contrôle immunitaires chez des patients atteints de mélanome cutané résistant aux anti-PD-1, en traitement de deuxième ligne ou plus Read article
- Nanobiotix names new CFO Read article
- NANOBIOTIX Announces the Appointment of Arnd Christ as Chief Financial Officer Read article
Related companies
Opening the full analysis uses 1 of your 3 free tickers today.
Educational tool only — not investment advice.